RT Journal Article
SR Electronic
T1 GWAS of Depression Phenotypes in the Million Veteran Program and Meta-analysis in More than 1.2 Million Participants Yields 178 Independent Risk Loci
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.18.20100685
DO 10.1101/2020.05.18.20100685
A1 Daniel F. Levey
A1 Murray B. Stein
A1 Frank R. Wendt
A1 Gita A. Pathak
A1 Hang Zhou
A1 Mihaela Aslan
A1 Rachel Quaden
A1 Kelly M. Harrington
A1 Gerard Sanacora
A1 Andrew M. McIntosh
A1 John Concato
A1 Renato Polimanti
A1 Joel Gelernter
A1 on behalf of the Million Veteran Program
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.18.20100685.abstract
AB We report a large meta-analysis of depression using data from the Million Veteran Program (MVP), 23andMe Inc., UK Biobank, and FinnGen; including individuals of European ancestry (n=1,154,267; 340,591 cases) and African ancestry (n=59,600; 25,843 cases). We identified 223 and 233 independent SNPs associated with depression in European ancestry and transancestral analysis, respectively. Genetic correlations within the MVP cohort across electronic health records diagnosis, survey self-report of diagnosis, and a 2-item depression screen exceeded 0.81. Using transcriptome-wide association study (TWAS) we found significant associations for gene expression in several brain regions, including hypothalamus (NEGR1, p=3.19×10−25) and nucleus accumbens (DRD2, p=1.87×10−20). 178 genomic risk loci were fine-mapped to find likely causal variants. We identified likely pathogenicity in these variants and overlapping gene expression for 17 genes from our TWAS, including TRAF3. This study sheds light on the genetic architecture of depression and provides new insight into the interrelatedness of complex psychiatric traits.Competing Interest StatementDr. Stein reports receiving consulting fees in the past 3 years from Aptinyx, Bionomics, Janssen, Jazz Pharmaceuticals, Neurocrine, Pfizer, and Oxeia Biopharmaceuticals. All other authors declare that they have no conflict of interest. No other conflicts are reported.In the last 12 months Dr. Sanacora has provided consulting services to Allergan, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celexio Biosciences, Epiodyne, Intra-Cellular Therapies, Janssen, Lundbeck, Minerva pharmaceuticals, Navitor Pharmaceuticals, NeuroRX, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Seelos Pharmaceuticals and Vistagen Therapeutics. He has received funds for contracted research from Janssen Pharmaceuticals, Merck, and Usona Institute. He is holds equity in Biohaven Pharmaceuticals and has received royalties from Yale University paid from patent licenses with Biohaven Pharmaceuticals.Dr. Gelernter is named as co-inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018.Funding StatementSupported by funding from the Veterans Affairs Office of Research and Development Million Veteran Program grant MVP011 and VA Cooperative Studies Program CSP575B. DFL was supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Central VA Institutional Review Board (IRB) and site-specific IRBs approved the MVP study. All relevant ethical regulations for work with human subjects were followed in the conduct of the study, and written informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics will be made available in dbGAP by the Million Veteran Program following publication. https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001672.v3.p1